Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency-Reference-Cited by-同舟云学术

Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency

Published:2015-01-21 Issue:3 Volume:21 Page:380-385
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Brand-Staufer B.¹,Carcao M.²,Kerlin B. A.³,Will A.⁴,Williams M.⁵,Tornøe C. W.⁶,Sandberg Lundblad M.⁶,Nugent D.⁷

Affiliation:

1. Division of Haematology; University Hospital Zurich; Zurich Switzerland

2. Division of Haematology/Oncology and Child Health Evaluative Sciences; Department of Paediatrics; Research Institute; Hospital for Sick Children; Toronto ON Canada

3. Nationwide Children's Hospital; Columbus OH USA

4. Royal Manchester Children's Hospital; Manchester UK

5. Birmingham Children's Hospital; Birmingham UK

6. Clinical Pharmacology; Novo Nordisk A/S; Søborg Denmark

7. Children's Hospital of Orange County; Children's Hospital and Center for Inherited Blood Disorders; Orange CA USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12616/fullpdf

Reference12 articles.

1. Factor XIII deficiency;Hsieh;Haemophilia,2008

2. Rare bleeding disorders;Peyvandi;Haemophilia,2008

3. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency;Lovejoy;Blood,2006

4. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency;Inbal;Blood,2012

5. Pharmacokinetics of recombinant FXIII at steady-state in patients with congenital FXIII A-subunit deficiency;Kerlin;J Thromb Haemost,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration;Blood;2024-02-01

2. Congenital Factor XIII Deficiency, Diagnosis, and Management;Congenital Bleeding Disorders;2023

3. The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison;Journal of Thrombosis and Thrombolysis;2022-09-12

4. Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence;Research and Practice in Thrombosis and Haemostasis;2022-02

5. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency;Clinical Pharmacokinetics;2021-10-31